TEVATeva Pharmaceutical Industries Limited

$36B

Q4 2017 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$5.5B-15.9% YoY

Gross Profit

$2.5B46.6% margin

Operating Income

-$13.0B-238.5% margin

Net Income

-$11.5B-211.3% margin

EPS (Diluted)

$-11.34

QoQ Revenue Growth

-2.7%

Cash Flow

Operating Cash Flow

$1.2B

Free Cash Flow

$912M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$70.6B

Total Liabilities

$51.9B

Stockholders' Equity

$17.4B

Cash & Equivalents

$963M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$5.5B	$6.5B	-15.9%
Gross Profit	$2.5B	$3.4B	-25.0%
Operating Income	-$13.0B	-$137M	-9401.5%
Net Income	-$11.5B	-$973M	-1085.5%

Revenue Segments

Branded

$1.8B38%

Branded CNS

$984M21%

Branded C N S Copaxone

$821M17%

Branded Respiratory Products

$293M6%

Branded Oncology Products

$283M6%

Other Branded Products

$167M3%

Branded Oncology Treanda and Bendeka

$157M3%

Branded Respiratory Proair

$102M2%

Branded Womens Health Products

$68M1%

Branded Respiratory Qvar

$61M1%

Branded C N S Azilect

$40M1%

Branded C N S Nuvigil

$9M0%

Geographic Segments

Rest Of The World

$169M70%

Europe Group Two

$71M30%